Abstract
Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR-aGVHD studies.
Original language | English (US) |
---|---|
Pages (from-to) | 429-432 |
Number of pages | 4 |
Journal | British journal of haematology |
Volume | 195 |
Issue number | 3 |
DOIs | |
State | Published - Nov 2021 |
Keywords
- graft-versus-host disease
- stem cell transplantation
- transplant
ASJC Scopus subject areas
- Hematology